VistaGen Therapeutics's total assets for Q1 2026 were $68.92M, a decrease of -18.28% from the previous quarter. VTGN total liabilities were $12.16M for the fiscal quarter, a -12.84% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.